Vetoquinol (PA:VETO) — Market Cap & Net Worth
Market Cap & Net Worth: Vetoquinol (VETO)
Vetoquinol (PA:VETO) has a market capitalization of $987.70 Million (€844.84 Million) as of July 7, 2026. Listed on the PA stock exchange, this France-based company holds position #9076 globally and #146 in its home market, demonstrating a -1.10% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vetoquinol's stock price €71.60 by its total outstanding shares 11799419 (11.80 Million). See capital reinvestment ratio of Vetoquinol to understand how much of operating cash flow is reinvested back into capital assets.
Vetoquinol Market Cap History: 2015 to 2026
Vetoquinol's market capitalization history from 2015 to 2026. Data shows growth from $505.00 Million to $987.70 Million (6.12% CAGR).
Index Memberships
Vetoquinol is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Health Care
FRHC
|
$255.21 Billion | 0.39% | #11 of 36 |
Weight: Vetoquinol's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Vetoquinol Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vetoquinol's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.92x
Vetoquinol's market cap is 1.92 times its annual revenue
Latest Price to Earnings (P/E) Ratio
17.61x
Vetoquinol's market cap is 17.61 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $505.00 Million | $342.61 Million | $24.16 Million | 1.47x | 20.91x |
| 2016 | $590.26 Million | $350.35 Million | $27.83 Million | 1.68x | 21.21x |
| 2017 | $791.39 Million | $352.17 Million | $34.83 Million | 2.25x | 22.72x |
| 2018 | $670.20 Million | $367.94 Million | $36.26 Million | 1.82x | 18.48x |
| 2019 | $857.45 Million | $395.99 Million | $28.59 Million | 2.17x | 29.99x |
| 2020 | $1.12 Billion | $427.47 Million | $19.22 Million | 2.62x | 58.29x |
| 2021 | $1.78 Billion | $521.27 Million | $62.86 Million | 3.41x | 28.28x |
| 2022 | $1.19 Billion | $539.78 Million | $47.99 Million | 2.20x | 24.74x |
| 2023 | $1.40 Billion | $529.27 Million | $55.56 Million | 2.65x | 25.22x |
| 2024 | $1.03 Billion | $539.20 Million | $58.69 Million | 1.92x | 17.61x |
Competitor Companies of VETO by Market Capitalization
Companies near Vetoquinol in the global market cap rankings as of July 7, 2026.
Key companies related to Vetoquinol by market ranking:
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #504 globally with a market cap of $52.99 Billion USD ( CN¥362.14 Billion CNY).
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #509 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #552 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #629 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #504 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $52.99 Billion | CN¥56.77 |
| #509 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #552 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $44.28 |
| #629 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.80 |
Vetoquinol Historical Marketcap From 2015 to 2026
Between 2015 and today, Vetoquinol's market cap moved from $505.00 Million to $ 987.70 Million, with a yearly change of 6.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €987.70 Million | -14.25% |
| 2025 | €1.15 Billion | +11.48% |
| 2024 | €1.03 Billion | -26.25% |
| 2023 | €1.40 Billion | +17.97% |
| 2022 | €1.19 Billion | -33.18% |
| 2021 | €1.78 Billion | +58.63% |
| 2020 | €1.12 Billion | +30.68% |
| 2019 | €857.45 Million | +27.94% |
| 2018 | €670.20 Million | -15.31% |
| 2017 | €791.39 Million | +34.08% |
| 2016 | €590.26 Million | +16.88% |
| 2015 | €505.00 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 7th, 2026 the market cap of Vetoquinol was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $987.70 Million USD |
| MoneyControl | $987.70 Million USD |
| MarketWatch | $987.70 Million USD |
| marketcap.company | $987.70 Million USD |
| Reuters | $987.70 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Vetoquinol
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal … Read more